“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Covis Pharmaceuticals


Covis Pharmaceuticals products


  • Altoprev® — lovastatin extended-release
    Indication: lowering cholesterol (dyslipidemia) in adults (statin therapy)

  • Alvesco® — ciclesonide inhalation aerosol
    Indication: maintenance therapy for asthma (inhaled corticosteroid)

  • Betapace® / Betapace AF® — sotalol
    Indication: treatment of arrhythmias (atrial fibrillation/flutter control)

  • Duaklir® Pressair® — aclidinium bromide/formoterol
    Indication: long-term maintenance treatment of COPD (LAMA/LABA combo)

  • Feraheme® — ferumoxytol
    Indication: intravenous iron therapy for iron deficiency anemia in patients with chronic kidney disease

  • Lanoxin® — digoxin
    Indication: heart failure and certain arrhythmias

  • Omnaris® — ciclesonide nasal spray
    Indication: allergic rhinitis (nasal allergy relief)

  • Prilosec® — omeprazole
    Indication: acid-related disorders like GERD and heartburn (proton pump inhibitor)

  • Sular® — nisoldipine
    Indication: hypertension management (calcium channel blocker)

  • Tudorza® Pressair® — aclidinium bromide
    Indication: maintenance treatment of COPD (long-acting muscarinic antagonist)




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)